R3HCC1L

Across TCGA pan-cancer cohorts, R3HCC1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated R3HCC1L data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher R3HCC1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated R3HCC1L expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

GBM, HNSC, and LSCC are the cancer types where R3HCC1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.268	0.520	.019	15	view →
HNSC	DFS	Median	III,IV	0.912	0.676	.007	13	view →
LSCC	OS	Median	II,III,IV	0.879	0.615	.015	6	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	4	view →
PDAC	OS	Median	III,IV	0.241	0.868	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

R3HCC1L–GBM (DFS)

Open the GBM breakdown →